Jasper Therapeutics (JSPR) 7th Annual Evercore ISI HealthCONx Conference summary

Program overview and clinical pipeline

• Lead program is a monoclonal antibody targeting c-Kit on mast cells, with three ongoing clinical trials in inducible urticaria, asthma, and chronic spontaneous urticaria (CSU).

• Top-line data for inducible urticaria was recently announced; first patient dosed in asthma trial; BEACON study in CSU will report top-line data the week of January 6th.

Dosing strategy and differentiation

• Optimal biologic dosing aims to deplete mast cells efficiently by reaching a specific Cmax, leveraging the biology of mast cell survival and apoptosis.

• Rapid onset of action observed, with most responders showing efficacy within a week in the SPOTLIGHT study.

• Dosing intervals longer than a month may allow for drug-free periods, potentially improving safety and convenience.

Safety profile and competitive positioning

• c-Kit is also present on stem cells, taste buds, melanocytes, and spermatogonia, so off-target effects are monitored.

• Dosing strategy may reduce adverse events like neutropenia and hair color changes by allowing bone marrow recovery between doses.

• No discontinuations, drug holidays, or reported anaphylaxis in the BEACON study to date.